S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
S&P 500   3,852.36
DOW   32,920.46
QQQ   303.59
Mullen Automotive Stock, The Tide Has Turned
Apple, Amazon, and Walmart are Investing in Solar Energy (Ad)
Energizer Holdings Inc; Losing Power Or Electrifying Time To Buy?
How to Find Penny Stocks to Invest and Trade
The #1 Energy Stock to Buy (Ad)
What Tyson Foods Q1 Means For Staples Stocks
ONSemi Is Marching Higher On Great Results
The #1 Energy Stock to Buy (Ad)
Can Cummins Power To A New High? 
Is BigBear.ai Stock a Diamond in the Rough?
NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$485.53
+3.12 (+0.65%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$462.60
$497.85
50-Day Range
$399.93
$504.22
52-Week Range
$317.06
$560.92
Volume
991,095 shs
Average Volume
575,232 shs
Market Capitalization
$40.21 billion
P/E Ratio
61.69
Dividend Yield
N/A
Price Target
$485.00

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
0.1% Downside
$485.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.80
Upright™ Environmental Score
News Sentiment
0.58mentions of IDEXX Laboratories in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$12.54 M Sold Last Quarter
Proj. Earnings Growth
19.75%
From $7.90 to $9.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

528th out of 1,027 stocks

Diagnostic Substances Industry

9th out of 15 stocks

IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in West

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
IDEXX Stumbles on Q4 and Full-Year Figures
IDEXX Laboratories Sees Higher Earnings, Revenues In FY23 - Update
IDEXX Laboratories Inc Q4 Income Climbs, Beats estimates
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
IDEXX Laboratories (NASDAQ:IDXX) Updates FY23 Earnings Guidance
IDXX.OQ - | Stock Price & Latest News | Reuters
A Preview Of IDEXX Laboratories's Earnings
IDEXX Laboratories Q4 2022 Earnings Preview
SONVY or IDXX: Which Is the Better Value Stock Right Now?
IDEXX Laboratories Is Barking Up the Right Tree
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings
2/06/2023
Today
2/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,350
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$485.00
High Stock Price Forecast
$582.00
Low Stock Price Forecast
$415.00
Forecasted Upside/Downside
-0.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$744.84 million
Pretax Margin
25.11%

Debt

Sales & Book Value

Annual Sales
$3.22 billion
Cash Flow
$10.08 per share
Book Value
$8.14 per share

Miscellaneous

Free Float
81,111,000
Market Cap
$40.21 billion
Optionable
Optionable
Beta
1.17

Social Links


Key Executives

  • Jonathan J. MazelskyJonathan J. Mazelsky
    President, Chief Executive Officer & Director
  • Brian Patrick McKeon
    Chief Financial Officer, Treasurer & Executive VP
  • Ken Grady
    Chief Information Officer & Senior VP
  • Murthy Yerramilli
    Senior Vice President-Research & Development
  • Martin Alexander Smith
    Chief Technology Officer & Executive VP













IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2023?

8 analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they predict the company's share price to reach $485.00 in the next year. This suggests that the stock has a possible downside of 0.1%.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2023?

IDEXX Laboratories' stock was trading at $407.96 on January 1st, 2023. Since then, IDXX shares have increased by 19.0% and is now trading at $485.53.
View the best growth stocks for 2023 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Monday, February, 6th. The company reported $2.05 EPS for the quarter, topping analysts' consensus estimates of $1.92 by $0.13. The firm earned $828.60 million during the quarter, compared to analyst estimates of $820.91 million. IDEXX Laboratories had a net margin of 20.05% and a trailing twelve-month return on equity of 118.38%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.89 EPS.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share guidance of $9.27-$9.75 for the period, compared to the consensus EPS estimate of $9.50. The company issued revenue guidance of $3.59 billion-$3.69 billion, compared to the consensus revenue estimate of $3.62 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by many different retail and institutional investors. Top institutional investors include LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Manning & Napier Group LLC (0.21%), Welch & Forbes LLC (0.21%) and Bank Julius Baer & Co. Ltd Zurich (0.20%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $485.53.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $40.21 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.87 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 10,350 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 2/7/2023 by MarketBeat.com Staff